Slide 1: Aquis Showcase: Innovative Products for Dermatology and Oncology
AQUIS SHOWCASE Innovative Products for Dermatology and Oncology 19 NOVEMBER 2025
Slide 2: Disclaimer
Disclaimer • The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the “Presentation”) have not been approved by an authorised person wit
Slide 3: Incanthera plc
Incanthera plc • Incanthera is a specialist company dedicated to innovative technologies in dermatology and oncology. • Established in 2010 as a spin out from the Institute of Cancer Therapeutics, University of Bradford. • Listed UK Aquis Stock Exchange (INC:AQSE), Feb 2020 • Incanthera’s recent foc
Slide 4: What is Skin+CELL?
What is Skin+CELL? • A revolutionary new skincare range utilising Incanthera’s unique cutting-edge delivery technology to deliver bioactive ingredients across the skin barrier • Independent studies have shown our targeted bioactive B3 formulations fortify the skin’s ability to protect itself and fac
Slide 5: DTC Campaign to date
DTC Campaign to date • Skin+CELL; establishing a new brand • Immediate positive feedback from Skin+CELL customers • SALES: achieved across product range, multiple hits across all the media platforms, valuable proprietary data and purchasing habits • Advisory group: DTC beauty/branding, pricing e- co
Slide 6: Looking Forward
Looking Forward • Active discussions ongoing to establish multiple routes to global markets for Skin + CELL through • DTC • Retail/Wholesale • Territorial Licensing • Collaboration with global high-profile celebrities • Introducing new products with different active ingredients utilising the unique
Slide 7: Previous Growth on Aquis
Previous Growth on Aquis • Deliver the newsflow and explain the potential for growth • Proactive relationships with Aquis Exchange on IR/PR initiatives • Promotion to Apex (top tier) segment of Aquis 10 June 2024 (since returned to Access) • Share Price: 6.5p (Jan 2024) to 26.5p (June 2024) • Share
Slide 8: Investment Summary
Investment Summary • Skin + CELL available through global DTC network and expanding into additional routes to market • First time revenues; attractive margins; cash generation • Potential for significant uplift in Company valuation and future shareholder returns 8